Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3356592 | 0.83 | DRD4 (0.55) | KCNH2SIGMAR1DRD2HTR1ACYP2D6 | |
| SCHEMBL18227891 | 0.80 | HTR7 (0.62) | HTR7KCNH2SIGMAR1DRD2HTR1A | |
| SCHEMBL9041083 | 0.80 | KCNH2 (0.80) | HTR7KCNH2SIGMAR1DRD2HTR1A | |
| SCHEMBL18227898 | 0.78 | HTR7 (0.60) | HTR7KCNH2SIGMAR1DRD2HTR1A | |
| SCHEMBL18227900 | 0.78 | HTR7 (0.60) | HTR7KCNH2SIGMAR1DRD2HTR1A | |
| SCHEMBL9742163 | 0.78 | GRM2 (0.61) | HTR7 | |
| SCHEMBL9742158 | 0.77 | HTR7 (0.59) | HTR7KCNH2SIGMAR1HTR1ACYP2D6 | |
| SCHEMBL9741902 | 0.77 | HTR7 (0.62) | HTR7KCNH2SIGMAR1DRD2DRD3 | |
| SCHEMBL9741903 | 0.77 | HTR7 (0.62) | HTR7KCNH2SIGMAR1DRD2DRD3 | |
| SCHEMBL9741906 | 0.77 | HTR7 (0.62) | HTR7KCNH2SIGMAR1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296249-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296249-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | DRD3, DRD2, SLC6A3 | HTR7 90/4885KCNH2 441/4885SIGMAR1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.